Nasdaq · CIK 0000907654
ORKA Oruka Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $82.11 on Oct 9, 2026, +235% from the 52-week low and -27% from the high.
Last 90 days
Net insider value
-$13M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
10
$13M by 5 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
ORKAOct 9, 2026 · close 82.11
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Oruka Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Lawrence Otto Klein Chief Executive Officer sell | $2.1M 25,000 shares | -3% | +348% from low-26% from high | |
| 17Weak | Arjun Agarwal Senior Vice President, Finance sell | $51k 533 shares | -4% | +520% from low-17% from high | |
| 29Weak | Paul T Quinlan General Counsel sell | $936k 10,000 shares | -25% | +520% from low-17% from high | |
| 29Weak | Arjun Agarwal Senior Vice President, Finance sell | $926k 10,019 shares | -40% | - | |
| 21Weak | Joana Goncalves Chief Medical Officer sell | $734k 7,947 shares | -20% | - | |
| 53Moderate | Lawrence Otto Klein Chief Executive Officer sell | $235k 2,452 shares | -0% | - | |
| 44Moderate | Laura Lee Sandler Chief Operating Officer sell | $87k 906 shares | -0% | - | |
| 40Moderate | Paul T Quinlan General Counsel sell | $99k 1,039 shares | -3% | - | |
| 30Weak | Lawrence Otto Klein Chief Executive Officer sell | $6.9M 75,000 shares | -7% | - | |
| 17Weak | Laura Lee Sandler Chief Operating Officer sell | $459k 5,000 shares | -2% | - | |
| 32Weak | Venrock Healthcare Capital Partners III, L.P. owner buy | $1.4M 122,882 shares | +3% | - |
Transactions
The last 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Lawrence Otto Klein Chief Executive Officer | MOption exercise Common Stock10b5-1 | +25,000 | $7.80 | $195k | 948,128 | 10 d ago |
| Oct 1, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -16,246 | $83.40 | $1.4M | 931,882 | 10 d ago |
| Oct 1, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -8,554 | $84.03 | $719k | 923,328 | 10 d ago |
| Oct 1, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -200 | $84.78 | $17k | 923,128 | 10 d ago |
| Oct 1, 2026 | Lawrence Otto Klein Chief Executive Officer | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 1,528,513 | 10 d ago |
| Sep 21, 2026 | Arjun Agarwal Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -533 | $95.75 | $51k | 14,219 | 21 d ago |
| Sep 21, 2026 | Paul T Quinlan General Counsel | MOption exercise Common Stock10b5-1 | +10,000 | $7.80 | $78k | 39,995 | 21 d ago |
| Sep 21, 2026 | Paul T Quinlan General Counsel | SOpen-market sale Common Stock10b5-1 | -2,900 | $92.37 | $268k | 37,095 | 21 d ago |
| Sep 21, 2026 | Paul T Quinlan General Counsel | SOpen-market sale Common Stock10b5-1 | -3,832 | $93.32 | $358k | 33,263 | 21 d ago |
| Sep 21, 2026 | Paul T Quinlan General Counsel | SOpen-market sale Common Stock10b5-1 | -601 | $94.44 | $57k | 32,662 | 21 d ago |
| Sep 21, 2026 | Paul T Quinlan General Counsel | SOpen-market sale Common Stock10b5-1 | -2,667 | $95.31 | $254k | 29,995 | 21 d ago |
| Sep 21, 2026 | Paul T Quinlan General Counsel | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 79,996 | 21 d ago |
| Sep 15, 2026 | Laura Lee Sandler Chief Operating Officer | SOpen-market sale Common Stock | -906 | $95.71 | $87k | 235,478 | 27 d ago |
| Sep 15, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock | -2,452 | $95.71 | $235k | 923,128 | 27 d ago |
| Sep 15, 2026 | Paul T Quinlan General Counsel | SOpen-market sale Common Stock | -1,039 | $95.71 | $99k | 29,995 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | MOption exercise Common Stock10b5-1 | +8,000 | $12.50 | $100k | 23,312 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | MOption exercise Common Stock10b5-1 | +3,500 | $6.84 | $24k | 36,218 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | MOption exercise Common Stock10b5-1 | +1,459 | $34.39 | $50k | 24,771 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | MOption exercise Common Stock10b5-1 | +3,500 | $7.80 | $27k | 39,718 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -3,000 | $91.11 | $273k | 21,771 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,384 | $91.10 | $217k | 37,334 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,150 | $92.03 | $290k | 34,184 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -4,051 | $92.41 | $374k | 17,720 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -2,208 | $93.26 | $206k | 15,512 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,366 | $92.99 | $127k | 32,818 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -100 | $94.22 | $9,422 | 32,718 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -200 | $94.02 | $19k | 15,312 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -947 | $95.71 | $91k | 31,771 | 27 d ago |
| Sep 15, 2026 | Arjun Agarwal Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -560 | $95.71 | $54k | 14,752 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -3,500 | $0.00 | $0 | 193,563 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 84,917 | 27 d ago |
| Sep 11, 2026 | Arjun Agarwal Senior Vice President, Finance | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,459 | $0.00 | $0 | 58,333 | 27 d ago |
| Sep 15, 2026 | Joana Goncalves Chief Medical Officer | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -3,500 | $0.00 | $0 | 164,992 | 27 d ago |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer | MOption exercise Common Stock10b5-1 | +75,000 | $7.80 | $585k | 1,000,580 | 41 d ago |
| Sep 1, 2026 | Laura Lee Sandler Chief Operating Officer | MOption exercise Common Stock10b5-1 | +5,000 | $7.80 | $39k | 241,384 | 41 d ago |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -6,604 | $90.79 | $600k | 993,976 | 41 d ago |
| Sep 1, 2026 | Laura Lee Sandler Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -1,000 | $91.05 | $91k | 240,384 | 41 d ago |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -63,596 | $91.90 | $5.8M | 930,380 | 41 d ago |
| Sep 1, 2026 | Laura Lee Sandler Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -4,000 | $92.01 | $368k | 236,384 | 41 d ago |
| Sep 1, 2026 | Laura Lee Sandler Chief Operating Officer | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 74,996 | 41 d ago |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -4,800 | $92.44 | $444k | 925,580 | 41 d ago |
| Sep 1, 2026 | Lawrence Otto Klein Chief Executive Officer | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -75,000 | $0.00 | $0 | 1,553,513 | 41 d ago |
| Sep 17, 2025 | Fairmount Funds Management LLC director, owner | AGrant or award Common Stockindirect: By Fairmount Healthcare Fund II L.P. | +333,340 | $15.00 | $5.0M | 1,131,954 | Sep 19, 2025 |
| Jun 2, 2025 | Kristine M Ball director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
| Jun 2, 2025 | Carl Dambkowski director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
| Jun 2, 2025 | Fairmount Funds Management LLC director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
| Jun 2, 2025 | Samarth Kulkarni director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
| Jun 2, 2025 | Cameron Turtle director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
| Feb 10, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +574 | $10.90 | $6,257 | 4,026,120 | Feb 27, 2025 |
| Feb 11, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +9,593 | $10.95 | $105k | 4,035,713 | Feb 27, 2025 |
| Feb 12, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +8,971 | $11.86 | $106k | 4,044,684 | Feb 27, 2025 |
| Feb 13, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +14,950 | $11.63 | $174k | 4,059,634 | Feb 27, 2025 |
| Feb 14, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +88,794 | $11.44 | $1.0M | 4,148,428 | Feb 27, 2025 |
| Jan 22, 2025 | Arjun Agarwal SVP, Finance | AGrant or award Employee Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jan 24, 2025 |
| Jan 22, 2025 | Joana Goncalves Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +162,500 | $0.00 | $0 | 162,500 | Jan 24, 2025 |
| Jan 22, 2025 | Lawrence Otto Klein Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Jan 24, 2025 |
| Nov 19, 2024 | Fairmount Funds Management LLC director, owner | MOption exercise Common Stockindirect: By Fairmount Healthcare Fund II L.P. | +160,000 | - | - | 798,614 | Nov 21, 2024 |
| Nov 19, 2024 | Fairmount Funds Management LLC director, owner | MOption exercise Series A Non-Voting Convertible Preferred Stockderivativeindirect: By Fairmount Healthcare Fund II L.P. | -160 | $0.00 | $0 | 0 | Nov 21, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Arjun AgarwalSenior Vice President, Finance
- Kristine M Balldirector
- Carl Dambkowskiofficer, director
- Fairmount Funds Management LLCdirector, owner
- Joana GoncalvesChief Medical Officer
- Lawrence Otto KleinChief Executive Officer
- Samarth Kulkarniceo, officer, director
- Paul T QuinlanGeneral Counsel
- Laura Lee SandlerChief Operating Officer
- Cameron Turtleceo, officer, director
- Venrock Healthcare Capital Partners III, L.P.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.